A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-20

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT04379518 / Suspended临床1/2期IIT

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

开始日期2020-11-17

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT04081389 / Completed临床1期IIT

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer. Chemokine modulation therapy, including celecoxib, recombinant interferon alfa-2b, and rintatolimod, may stimulate the immune system and stop tumor cells from growing. Drugs used in standard chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemokine modulation therapy together with standard chemotherapy may work better than giving either therapy alone in treating patients with triple negative breast cancer.

开始日期2019-12-06

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的临床结果

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的转化医学

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的专利（医药）

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
尖锐湿疣	墨西哥	Probiomed SA de CV	2006-03-01
毛细胞白血病	墨西哥	Probiomed SA de CV	2006-03-01
乙型肝炎	墨西哥	Probiomed SA de CV	2006-03-01
丙型肝炎	墨西哥	Probiomed SA de CV	2006-03-01
卡波西肉瘤	墨西哥	Probiomed SA de CV	2006-03-01
黑色素瘤	墨西哥	Probiomed SA de CV	2006-03-01
多发性骨髓瘤	墨西哥	Probiomed SA de CV	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03403634 (CTgov)	临床2期	肝转移 \| 复发性结直肠癌 \| 结直肠癌	19	Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib	簾糧鏇膚範鹽鹽廠憲齋(鑰鑰襯網範築窪鬱齋窪) = 繭繭窪鬱壓鹽糧糧顧淵顧餘鏇觸艱壓齋齋壓觸 (遞積襯壓範繭膚鬱鹽選, 遞窪觸廠網鏇淵衊艱壓 ~ 遞獵選簾廠積糧獵壓積) 更多	-	2022-03-02
NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sorafenib Tosylate (Sorafenib Tosylate)	餘鏇鹹衊廠鬱鑰窪積選(窪蓋獵簾齋淵蓋顧築繭) = 範範壓築糧膚構獵構鏇鑰繭夢襯醖構鹹遞構蓋 (窪窪遞積簾齋構壓餘糧, 膚淵餘鬱範遞鹽醖夢構 ~ 衊糧襯壓顧鏇襯餘壓壓) 更多	-	2016-09-16
NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sch 30500+Heberon Alfa+Urifron+Sorafenib Tosylate (Sorafenib Tosylate, Recombinant Interferon Alfa-2b)	餘鏇鹹衊廠鬱鑰窪積選(窪蓋獵簾齋淵蓋顧築繭) = 糧積夢網艱憲醖鑰蓋窪鑰繭夢襯醖構鹹遞構蓋 (窪窪遞積簾齋構壓餘糧, 憲衊願蓋獵獵蓋鏇淵醖 ~ 齋築築顧鬱範繭積願窪) 更多	-	2016-09-16